Barclays’s HCA Healthcare HCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-18,900
| Closed | -$5.12M | – | 5196 |
|
|
2023
Q4 | $5.12M | Sell |
18,900
-18,900
| -50% | -$4.67M | ﹤0.01% | 2069 |
|
|
2023
Q3 | $9.3M | Sell |
37,800
-43,200
| -53% | -$11.8M | 0.01% | 1027 |
|
|
2023
Q2 | $24.6M | Buy |
+81,000
| New | +$22.5M | 0.02% | 652 |
|
|
2023
Q1 | – | Sell |
-3,600
| Closed | -$864K | – | 5196 |
|
|
2022
Q4 | $864K | Buy |
+3,600
| New | +$806K | ﹤0.01% | 2934 |
|
|
2021
Q1 | – | Sell |
-45,500
| Closed | -$7.48M | – | 4900 |
|
|
2020
Q4 | $7.48M | Buy |
45,500
+13,500
| +42% | +$1.97M | ﹤0.01% | 1298 |
|
|
2020
Q3 | $3.99M | Sell |
32,000
-2,400
| -7% | -$297K | ﹤0.01% | 1552 |
|
|
2020
Q2 | $3.34M | Sell |
34,400
-10,900
| -24% | -$1.13M | ﹤0.01% | 1679 |
|
|
2020
Q1 | $4.07M | Sell |
45,300
-33,500
| -43% | -$4.34M | ﹤0.01% | 1649 |
|
|
2019
Q4 | $11.6M | Sell |
78,800
-6,000
| -7% | -$806K | 0.01% | 1278 |
|
|
2019
Q3 | $10.2M | Buy |
84,800
+32,000
| +61% | +$4.14M | 0.01% | 1270 |
|
|
2019
Q2 | $7.14M | Buy |
52,800
+5,300
| +11% | +$670K | ﹤0.01% | 1562 |
|
|
2019
Q1 | $6.19M | Sell |
47,500
-58,200
| -55% | -$7.82M | ﹤0.01% | 1509 |
|
|
2018
Q4 | $13.2M | Sell |
105,700
-5,500
| -5% | -$738K | 0.01% | 997 |
|
|
2018
Q3 | $15.5M | Buy |
111,200
+300
| +0.3% | +$37.3K | 0.01% | 994 |
|
|
2018
Q2 | $11.4M | Sell |
110,900
-700
| -0.6% | -$70.8K | 0.01% | 1128 |
|
|
2018
Q1 | $10.8M | Buy |
111,600
+45,900
| +70% | +$4.45M | 0.01% | 1141 |
|
|
2017
Q4 | $5.77M | Sell |
65,700
-58,400
| -47% | -$4.69M | ﹤0.01% | 1562 |
|
|
2017
Q3 | $9.88M | Buy |
124,100
+103,200
| +494% | +$8.3M | 0.01% | 1067 |
|
|
2017
Q2 | $1.82M | Buy |
20,900
+4,900
| +31% | +$415K | ﹤0.01% | 2347 |
|
|
2017
Q1 | $1.42M | Sell |
16,000
-96,600
| -86% | -$8.05M | ﹤0.01% | 2401 |
|
|
2016
Q4 | $8.33M | Sell |
112,600
-13,700
| -11% | -$1.03M | 0.01% | 1046 |
|
|
2016
Q3 | $9.55M | Buy |
126,300
+85,700
| +211% | +$6.56M | 0.01% | 899 |
|
|
2016
Q2 | $3.13M | Sell |
40,600
-11,200
| -22% | -$884K | ﹤0.01% | 1658 |
|
|
2016
Q1 | $4.04M | Sell |
51,800
-229,200
| -82% | -$16M | 0.01% | 1346 |
|
|
2015
Q4 | $18.8M | Buy |
281,000
+180,500
| +180% | +$12.6M | 0.02% | 595 |
|
|
2015
Q3 | $7.74M | Sell |
100,500
-367,900
| -79% | -$32.6M | 0.01% | 1087 |
|
|
2015
Q2 | $42.2M | Buy |
468,400
+359,600
| +331% | +$28.8M | 0.05% | 348 |
|
|
2015
Q1 | $8.16M | Sell |
108,800
-86,900
| -44% | -$6.24M | 0.01% | 1208 |
|
|
2014
Q4 | $14.3M | Buy |
195,700
+76,100
| +64% | +$5.35M | 0.01% | 956 |
|
|
2014
Q3 | $8.37M | Sell |
119,600
-79,800
| -40% | -$5.27M | 0.01% | 1314 |
|
|
2014
Q2 | $11.2M | Buy |
199,400
+166,900
| +514% | +$8.81M | 0.01% | 1066 |
|
|
2014
Q1 | $1.69M | Sell |
32,500
-20,200
| -38% | -$1.01M | ﹤0.01% | 2717 |
|
|
2013
Q4 | $2.48M | Sell |
52,700
-74,300
| -59% | -$3.43M | ﹤0.01% | 2447 |
|
|
2013
Q3 | $5.33M | Buy |
127,000
+102,200
| +412% | +$3.99M | 0.01% | 1624 |
|
|
2013
Q2 | $895K | Buy |
+24,800
| New | +$959K | ﹤0.01% | 3528 |
|
Other funds holding HCA
VCM
VPM
Barclays's HCA Position: Q1 2026 in Review
Barclays reduced its HCA Healthcare (HCA) stake by 5.6% in Q1 2026, selling an estimated $37.2M and leaving 1,248,315 shares worth $591M. The position accounts for 0.14% of the portfolio, ranked #110.
Barclays first reported a position in HCA in Q2 2013 and has held it in 52 quarters since. The position peaked at $617M in Q4 2025. 1,414 funds tracked by Wall St. Rank hold HCA as of Q1 2026.
- Barclays held 1,248,315 shares of HCA Healthcare worth $591M as of Q1 2026.
- Barclays sold 73,896 HCA Healthcare shares in Q1 2026, an estimated $37.2M.
- HCA Healthcare made up 0.14% of Barclays's portfolio in Q1 2026, its #110 holding.
- Barclays first reported a position in HCA Healthcare in Q2 2013 and has held it in 52 quarters since.
- Barclays's HCA Healthcare position peaked at $617M in Q4 2025.
- 1,414 funds tracked by Wall St. Rank held HCA Healthcare as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.